European Biotech Acquisition Corp. - Class A
The momentum for this stock is not very good. European Biotech Acquisition Corp. - Class A is not very popular among insiders. Tradey thinks it is not wise to invest in European Biotech Acquisition Corp. - Class A.
Log in to see more information.
News
Oculis Announces US Public Listing on NASDAQ
Globe Newswire Oculis Announces US Public Listing on NASDAQ Closing of business combination with European Biotech Acquisition Corp. creates Nasdaq-listed ophthalmology company, under the ticker OCS,with advanced clinical-stage pipeline of multiple product candidates in key areas of medical needs such as retina, ...\n more…